Neion Bio CEO: genetically engineered chickens producing medicines inside eggs could slash drug costs

Summary

Demi Clari, co-founder and CEO of Neon Bio, emerged from stealth to pitch a platform built around a simple biological observation: chickens have spent 250 million years evolving into efficient protein factories, converting grain and water into complex proteins inside their eggs. Most modern medicines are themselves complex proteins, so Neon Bio genetically engineers chickens to produce those medicines directly in the egg.

The manufacturing logic is straightforward. Current biologic drug production relies on expensive, fragile global supply chains, which is a large part of why drugs like Humira or Keytruda can cost thousands to tens of thousands of dollars per dose. Neon Bio's pitch is that chickens are a cheaper, scalable alternative. A few thousand birds, Clari says, can produce the global supply of a drug like Humira. A single chicken can treat between 10 and 100 patients per year depending on the medicine. Scaling means breeding more chickens, which is linear and well understood.

To reduce regulatory and commercial risk early on, Neon Bio is starting with biosimilars — drugs that already exist, already work, and already have established demand. The company announced a commercial deal to bring up to three drugs to market with an undisclosed partner. Clari's framing is that biosimilars let the company prove out its manufacturing platform without taking on molecular risk, while addressing a market where cost pressure is already acute.

Caffeinated Capital is an investor in Neon Bio. Clari's background is aerospace engineering, which he connects to biotech through a shared interest in manufacturing complex things at scale. Whether the chicken platform can generate competitive yields and navigate the biosimilar approval process fast enough to matter before IP windows close is the open question the segment doesn't resolve.